top of page
Backgrounds.jpg

The voice of Colville and northeastern Washington since 1896

|

September 15, 2026

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

106.94 -3.46 (-3.13%)
Delayed Quote Updated: 4:00 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Unpacking Q2 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Halozyme Therapeutics (NASDAQ:HALO) and its peers. O... 
Via StockStory
Topics Artificial Intelligence
News headline image
Biogen (NASDAQ:BIIB) Q2 Earnings: Leading The Therapeutics Pack
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Bioge... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Cash-Producing Stock to Target This Week and 2 We Question
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
Via StockStory
Halozyme Therapeutics (NASDAQ:HALO) Screens Well on High Growth Momentum and Breakout Setup ↗
Via Chartmill
News headline image
Argenx Has Delivered 18 Consecutive Quarters of Sales Growth -- but Is the Biotech Stock Still Underrated? ↗
This biotech innovator could be in only the early chapters of its success story. 
Via The Motley Fool
Halozyme Therapeutics (NASDAQ:HALO) Meets Minervini’s High-Growth Trend Template ↗
Via Chartmill
Halozyme Therapeutics (NASDAQ:HALO) Demonstrates Strong Quality Investing Characteristics Across All Key Metrics ↗
Via Chartmill
News headline image
1 Mid-Cap Stock on Our Watchlist and 2 We Avoid
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe... 
Via StockStory
Topics Fraud
News headline image
3 Market-Beating Stocks for Long-Term Investors
Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital. The select few that ca... 
Via StockStory
News headline image
1 Healthcare Stock with Exciting Potential and 2 We Avoid
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have be... 
Via StockStory
Topics Economy
News headline image
2 Mid-Cap Stocks with Solid Fundamentals and 1 Facing Challenges
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe... 
Via StockStory
Halozyme Therapeutics (NASDAQ:HALO): A Value Stock Profile Offering Strong Profitability and a Low Forward P/E ↗
Via Chartmill
Halozyme Therapeutics Inc (NASDAQ:HALO): A Deep Value Play Combining Strong Profitability with an Attractive 14.35 P/E ↗
Via Chartmill
News headline image
Halozyme (HALO) Q2 2026 Earnings Call Transcript ↗
Revenue jumped 48% to $481 million on record royalty growth. 
Via The Motley Fool
Topics Earnings
News headline image
The Top 5 Analyst Questions From Halozyme Therapeutics’s Q2 Earnings Call
Halozyme Therapeutics delivered a notably positive second quarter, as evidenced by the strong market reaction and management’s attribution of outperformance ... 
Via StockStory
Topics Earnings Intellectual Property
News headline image
HALO Q2 Deep Dive: Royalty Diversification and New Pipeline Drive Upgraded Guidance
Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) announced better-than-expected revenue in Q2 CY2026, with sales up 47.7% year on ... 
Via StockStory
News headline image
Halozyme Therapeutics (HALO) Shares Skyrocket, What You Need To Know
What Happened? Shares of biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) jumped 18.1% in the afternoon session after the company ... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Profitable Stock to Research Further and 2 We Ignore
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does... 
Via StockStory
News headline image
Halozyme Therapeutics Q2 Earnings Call Highlights ↗
Halozyme Therapeutics (NASDAQ:HALO) reported record second-quarter revenue and raised its full-year outlook, citing growth in royalty income from its ENHANZE drug-delivery platform, contributions from... 
Via MarketBeat
Topics Earnings
News headline image
Halozyme Therapeutics (NASDAQ:HALO) Beats Expectations in Strong Q2 CY2026, Guides for Strong Full-Year Sales
Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales... 
Via StockStory
News headline image
What To Expect From Halozyme Therapeutics’s (HALO) Q2 Earnings
Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) will be announcing earnings results this Thursday after the bell. Here’s what to ... 
Via StockStory
News headline image
3 Growth Stocks Set to Flourish
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 wil... 
Via StockStory
News headline image
1 Cash-Producing Stock on Our Watchlist and 2 We Ignore
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient... 
Via StockStory
Topics Energy
News headline image
1 Value Stock Worth Investigating and 2 Facing Headwinds
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether t... 
Via StockStory
News headline image
2 Reasons to Like HALO and 1 to Stay Skeptical
Halozyme Therapeutics trades at $78.57 and has moved in lockstep with the market. Its shares have returned 8.5% over the last six months while the S&P 500 ha... 
Via StockStory
Topics Stocks
News headline image
1 Surging Stock for Long-Term Investors and 2 We Brush Off
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements... 
Via StockStory
News headline image
2 Profitable Stocks Worth Your Attention and 1 We Question
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi... 
Via StockStory
Topics Credit Cards
News headline image
Why Is Halozyme Therapeutics (HALO) Stock Rocketing Higher Today
What Happened? Shares of biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) jumped 5.2% in the afternoon session after an analyst re... 
Via StockStory
Topics Economy
News headline image
Halozyme Therapeutics’s Q1 Earnings Call: Our Top 5 Analyst Questions
Halozyme Therapeutics’ first quarter results for 2026 were met with a positive market response, underpinned by substantial royalty revenue growth and the exp... 
Via StockStory
Topics Earnings
News headline image
Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% annually, with servi... 
Via StockStory
Topics Economy
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
bottom of page